
Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead

Redeye provides a research update on Faron Pharmaceuticals following the company's recent H1 report. With upcoming BEXMAB read-outs, a planned pivotal study and a potential license deal on the horizon, we see promising times ahead for the company. Following the company's recent clinical progression, positive FDA feedback and a granted Fast Track Designation, we increase our base case valuation to EUR2.8 (2) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Faron Pharmaceuticals H1 - Turbulent times behind, promising times ahead](#)